Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 332–333 (2007)Cite this article

boxed-textEdelman S et al. (2006) A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29: 2189–2195

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Edelman SV et al. (2006) Pramlintide in the treatment of diabetes. Int J Clin Pract 60: 1647–1653

    Article  CAS  Google Scholar 

  2. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820

    Article  CAS  Google Scholar 

  3. Ceriello A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54: 1–7

    Article  CAS  Google Scholar 

  4. Monnier L et al. (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295: 1681–1687

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Metabolic Diseases, Lapeyronie Hospital, 371 Avenue du Doyen G, Giraud, 34295 Montpellier Cedex 5, France

Authors and Affiliations

  1. L Monnier is a Professor of Endocrinology at the University of Montpellier I and Head of the Department of Metabolic Diseases, Lapeyronie Hospital, Montpellier, France.,

    Louis Monnier

Authors
  1. Louis Monnier
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monnier, L. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?. Nat Rev Endocrinol 3, 332–333 (2007). https://doi.org/10.1038/ncpendmet0454

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0454

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing